Verve is developing RNA interference therapeutics targeting non-alcoholic fatty liver disease, with lead compounds in preclinical validation. The team includes researchers from University of Melbourne's Gastroenterology Unit. Two independent milestone grants from NHMRC and one collaborative partnership with a leading hepatology clinic.